Medicare has launched an 18-month pilot called the Bridge program to offer GLP-1 weight loss medications for $50 a month.. However, the initiative is currently exccluding millions of enrollees who require these drugs to treat existing conditions like sleep apnea or Type 2 diabetes.
The Basking Ridge dilemma: How sleep apnea blocks $50 access
Jeff La Marca, a retired professor living in Basking Ridge, New Jersey, exemplifies the program's unintended consequences. Despite having a BMI of 42 and a history of surviving quadruple heart bypass surgery, La Marca was denied the $50 monthly rate for his Zepbound prescription. The report notes that because he uses a continuous positive airway pressure device to treat severe obstructive sleep apnea, he is ineligible for the Bridge program's discount.
Instead of the $50 rate, La Marca and others in similar positions are redirected to Medicare Part D. This shift can reult in monthly copays of several hundred dollars , making life-saving medication financially impossible for many. For La Marca, who also faces the threat of stroke and is prediabetic, the inability to access affordable medication is a significant blow to his long-term health management.
A $10 billion pilot with a massive coverage gap
The Bridge program is an 18-month initiative designed to test whether covering GLP-1 drugs can reduce future medical spending by preventing obesity-related complications. While the program aims to help,it has created a coverage gap affecting an estimated 5.9 million Medicare enrollees. These individuals are overweight enough to qualify for a GLP-1 prescription but are unable to benefit from the Bridge discount because they already have a condition that the medications are formally approved to treat.
Financial projections for the pilot vary significantly based on participation levels. According to independent analysis cited in the report, if just 25% of eligible patients enroll and stay for the full term, the cost could reach $3.3 billion; however, if 75% of patients enroll, the price tag could climb to roughly $10 billion. Expanding the program to include the 5.9 million excluded patients would add billions more to the federal budget.
The FDA-approved carve-out that ignores medical necessity
The program's current structure includes a critical restriction:the $50 price point applies only to patients using medication solely for weight loss.. If a patient has a condition that the FDA has already approved GLP-1s to treat—such as Type 2 diabetes or moderate to severe sleep apnea—they are excluded from the Bridge discount. This rule also affects patients with a BMI between 27 and 34 who may have cardiovascular disease or prediabetes.
Juliette Cubanski, who directs the Program on Medicare Policy at KFF, explained that the program was intended to reach those who could not otherwise obtain coverage through Part D. However, this creates a paradox where the patients with the highest medical need are the ones most likely to be priced out. By focusing on those using the drugs for weight loss alone , the program may be overlooking the very demographic that would see the most immediate medical benefits.
Will CMS address the exclusion of 5.9 million enrollees?
While a spokesperson for the Centers for Medicare and Medicaid Services (CMS) stated that the early weeks of the demonstration have run smoothly, the agency has not addressed the specific criticisms regarding patient exclusion. It remains unclear if the government intends to adjust the program's criteria to include those with pre-existing conditions or if the current "weight loss only" rule is a permanent feature of the pilot.
The source does not clarify whether the exclusion is a deliberate cost-saving measure or a regulatory oversight. Furthermore, there is no official word on whether the $50 rate will eventually be extended to the 5.9 million people currently caught in the regulatory gap, leaving their access to affordable GLP-1 medications in a state of uncertainty.
Comments 0